SCHEMBL631892

SCHEMBL631892

Cc1c(S(=O)(=O)O)c2ccccc2n1C

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 5/20 0.53
▸ ALDH1A1 P00352 3/20 0.53
▸ HPGD P15428 2/20 0.53
▸ HSD17B10 Q99714 2/20 0.53
▸ GAA P10253 2/20 0.53
▸ GLA P06280 1/20 0.53
▸ CYP2C19 P33261 1/20 0.53
▸ HTT P42858 1/20 0.53
▸ ACLY P53396 1/20 0.48
▸ TDP1 Q9NUW8 2/20 0.47
▸ KMT2A Q03164 2/20 0.47
▸ MEN1 O00255 1/20 0.47
▸ MAPT P10636 1/20 0.47
▸ GPR3 P46089 1/20 0.47
▸ NPSR1 Q6W5P4 2/20 0.46
▸ NQO2 P16083 1/20 0.43
▸ SRC P12931 3/20 0.42
▸ EGFR P00533 2/20 0.42
▸ POLB P06746 1/20 0.42
▸ APEX1 P27695 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Pyridine SCHEMBL632139 0.89 ACLY (0.45) KDM4EALDH1A1HPGDHSD17B10GAA
SCHEMBL20050622 0.84 KDM4E (0.50) KDM4EALDH1A1HPGDHSD17B10GAA
SCHEMBL631543 0.82 KDM4E (0.49) KDM4EALDH1A1HPGDHSD17B10GAA
SCHEMBL11321983 0.79 KDM4E (0.43) KDM4EALDH1A1HPGDHSD17B10HTT
SCHEMBL7819876 0.78 ALDH1A1 (0.56) KDM4EALDH1A1HPGDHSD17B10GAA
SCHEMBL11330268 0.78 ALDH1A1 (0.50) KDM4EALDH1A1HPGDHSD17B10CYP2C19
SCHEMBL11339416 0.78 ALDH1A1 (0.58) KDM4EALDH1A1HPGDHSD17B10CYP2C19
SCHEMBL27597589 0.77 KDM4E (0.39) KDM4EALDH1A1HPGDHSD17B10GAA
SCHEMBL11517081 0.73 CNR1 (0.38) KDM4EALDH1A1HTTTDP1KMT2A
SCHEMBL11517395 0.73 HTR6 (0.43) KDM4EALDH1A1TDP1POLBAPEX1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10407389-B2 Method for the preparation of H-Arg(MIS)-OH POLYPEPTIDE LABORATORIES HOLDING (PPL) AB (SE) 2019-09-10 — — US disclosed
US-20190241517-A1 Method for the Preparation of H-Arg(MIS)-OH POLYPEPTIDE LABORATORIES HOLDING PPL AB (SE) 2019-08-08 — — US disclosed
EP-3315490-A1 METHOD FOR THE PREPARATION OF H-ARG(MIS)-OH Polypeptide Laboratories Holding (PPL) AB (SE) 2018-05-02 — — EP disclosed
WO-2018064829-A1 METHOD FOR THE PREPARATION OF H-ARG (MIS) -OH POLYPEPTIDE LABORATORIES HOLDING (PPL) AB (SE) 2018-04-12 — — WO disclosed
EP-3305780-A1 METHOD FOR THE PREPARATION OF H-ARG(MIS)-OH Lonza Ltd (CH) 2018-04-11 — — EP disclosed
EP-2420489-B1 Indolesulfonyl protecting groups for protection of guanidino and amino groups LONZA AG (CH) 2014-04-23 — — EP disclosed
CN-101578265-B Sulfonamide derivatives as chymase inhibitors HOFFMANN LA ROCHE 2013-05-08 — — CN disclosed
US-8431720-B2 Indolesulfonyl protecting groups for protection of guanidino and amino groups LONZA LTD. (CH) 2013-04-30 — — US disclosed
EP-2420489-A1 Indolesulfonyl protecting groups for protection of guanidino and amino groups Lonza Ltd (CH) 2012-02-22 — — EP disclosed
CN-102026971-A Indolesulfonyl protecting groups for protection of guanidino and amino groups LONZA AG 2011-04-20 — — CN disclosed
US-20110060125-A1 INDOLESULFONYL PROTECTING GROUPS FOR PROTECTION OF GUANIDINO AND AMINO GROUPS POLYPEPTIDE LABORATORIES HOLDING (PPL) AB (SE) 2011-03-10 — — US disclosed
CN-101578265-A Sulfonamide derivatives as chymase inhibitors HOFFMANN LA ROCHE (CH) 2009-11-11 — — CN disclosed
US-4243584-A Monoazo dyestuffs containing diazo component substituted by disulfimide and trifluoromethyl groups BAYER AKTIENGESELLSCHAFT (DE) 1981-01-06 — — US disclosed
US-4159265-A Phenylazopyrazolo dyestuffs including disulfimide substituent BAYER AKTIENGESELLSCHAFT (DE) 1979-06-26 — — US disclosed
US-4000123-A POLYAMIDES BAYER AKTIENGESELLSCHAFT (DT) 1976-12-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10407389-B2 Method for the preparation of H-Arg(MIS)-OH ARG1, HNMT, PRMT3 KDM4E 2232/4885ALDH1A1 2269/4885HPGD 327/4885
US-20110060125-A1 INDOLESULFONYL PROTECTING GROUPS FOR PROTECTION OF GUANIDINO AND AMINO GROUPS INMT, IDO1, IDO2 KDM4E 399/4885ALDH1A1 1372/4885HPGD 1944/4885
US-20190241517-A1 Method for the Preparation of H-Arg(MIS)-OH ARG1, HNMT, PRMT3 KDM4E 2232/4885ALDH1A1 2269/4885HPGD 327/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback